The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Churyukanov V.V.

Sechenov First Moscow State Medical University

Churyukanov M.V.

Sechenov First Moscow State Medical University (Sechenov University);
Petrovsky National Research Centre of Surgery

Ketamine: an «atypical» antidepressant, a new effect of the old analgesic

Authors:

Churyukanov V.V., Churyukanov M.V.

More about the authors

Journal: Russian Journal of Pain. 2021;19(1): 40‑45

DOI: 10.17116/pain20211901140

Read: 22187 times

Download PDF (RU)
Contact the author
Table of contents

KETAMINE: AN «ATYPICAL» ANTIDEPRESSANT, A NEW EFFECT OF THE OLD ANALGESIC
KETAMINE: AN «ATYPICAL» ANTIDEPRESSANT, A NEW EFFECT OF THE OLD ANALGESIC

To cite this article:

Churyukanov VV, Churyukanov MV. Ketamine: an «atypical» antidepressant, a new effect of the old analgesic. Russian Journal of Pain. 2021;19(1):40‑45. (In Russ.)
https://doi.org/10.17116/pain20211901140

Подписка 2025 Российский журнал боли (Russian Journal of Pain)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The gut microbiota in bipo­lar diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):28-33
Como­rbidity of depression and deme­ntia: epidemiological, biological and therapeutic aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121
Online phenotypes of depression symptoms are asso­ciated with poly­genic risk scores of soma­tic diseases in a popu­lation-based cohort. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):122-131
Asso­ciation between the vita­min D level and depression in the elde­rly people in the Euro­pean North of Russia. Russian Journal of Preventive Medi­cine. 2024;(12):107-113
Atopic dermatitis and skin toxic reactions: comparative characteristics, psychosomatic aspe­cts and patient mana­gement tactics. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):744-752
Subjective sleep quality evaluation in patients with neuromyelitis optica spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):57-61
Pathogenetic inte­rrelations of hypo­gonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23
Nutritional care for patients with neurodegenerative diseases in the outpatient practice of a neurologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):76-83
A personalized approach to the treatment of chro­nic tension headache and como­rbid mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):51-57
Expe­rience with the use of amitriptyline for chro­nic pelvic pain asso­ciated with endo­metriosis. Russian Journal of Human Reproduction. 2025;(1):86-93
Abstract:

The main disadvantages of modern antidepressants are slow therapeutic response and ineffectiveness in a significant number of patients. The «dissociative» anesthetic and non-opioid analgesic ketamine (NMDA receptor antagonist) ensures fast and significant effect in refractory depression. However, widespread use of ketamine is complicated by its psychotomimetic effects and narcogenic potential. Experimental and clinical studies indicate the multicomponent mechanism of antidepressant effect of ketamine: direct inhibition of synaptic and extra-synaptic NMDA receptors, activation of AMPA receptors, regulation of synaptic plasticity, etc. Metabolites of ketamine are also essential in antidepressant effect.

Keywords:

depression
ketamine
antidepressant effect
NMDA receptor
AMPA receptor
ketamine metabolites
synaptic plasticity

Authors:

Churyukanov V.V.

Sechenov First Moscow State Medical University

Churyukanov M.V.

Sechenov First Moscow State Medical University (Sechenov University);
Petrovsky National Research Centre of Surgery

Received:

25.01.2021

Accepted:

27.01.2021

Close metadata

References:

  1. Murray CJ, Vos T, Lorano R, et al. Disabitity-adjasted life years (DALY) for 291 diseases and injuries in 21 regions, 1990-2010; a systemic analysis. Lancet. 2012;380:2197-2223. https://doi.org/10.1016/S0140-6736(12)61689-4
  2. O’Donnel JM, Bies RR, Shelton RC. Drug therapy of depression and anxiety disorders. In: Goodman and Gilman’s. The Pharmacological Basis of Therapeutics, 13th edition; 2018;267-277. 
  3. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol. 1999;375(1-3):31-40. 
  4. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990 Aug 21;185(1):1-10. PMID: 2171955. https://doi.org/10.1016/0014-2999(90)90204-j
  5. Lodge D, Mercier MS. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol. 2015;172(17):4254-4276. Epub 2015 July 28. PMID: 26075331; PMCID: PMC4556466. https://doi.org/10.1111/bph.13222
  6. Patel H, Pearn ML, Patel PM, Roth DM. General anaesthetics and therapeutic gases. In: Goodman and Gilman’s. The Pharmacological Basis of Therapeutics, 13th edition; 2018:387-404. 
  7. Peltoniemi M.A., Hagelberg N.M. Oikkola et al. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anaesthesia and pain therapy. Clin Pharmacocinet. 2016;55:1059-1077.
  8. Berman R.M. Antidepressant effect of ketamine in depressed patients. Biol Psychiatry. 2000;47:351-354. 
  9. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939-946. PubMed: 22297150.
  10. Zarate CA. A randomized trial of an NMDA-antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-864. 
  11. Zefirov AL, Sitdikova GF. Ionnye kanaly vozbudimoj kletki (struktura, funktsiya, patologiya), Kazan: Art-kafe; 2010.
  12. Adell A. Brain NMDA Receptors in Schizophrenia and Depression. Biomolecules. 2020;10(6):947. PMID: 32585886; PMCID: PMC7355879. https://doi.org/10.3390/biom10060947
  13. Skolnick P, Popik P, Trullas R. Glutamate-based antideptessants: 20 years on. Trends Pharm Sci. 2009;30:563-569. 
  14. Yang C, Yang J, Luo A, et al. Molecular and cellular underlying the antidepressant effects of ketamine enantiomers and its metabolites. Translational Psychiatry. 2019;9:280-291. 
  15. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry. 1997;154(6):805-811. PubMed: 9167508.
  16. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007;27(43):11496-11500. PubMed: 17959792.
  17. Neske GT, Patrick SL, Connors BW. Contributions of diverse excitatory and inhibitory neurons to recurrent network activity in cerebral cortex. J Neurosci. 2015;35(3):1089-1105. PubMed: 25609625.
  18. Seamans J. Losing inhibition with ketamine. Nat Chem Biol. 2008;4(2):91-93. PubMed: 18202677.
  19. Kotermanski SE, Johnson JW. Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer’s drug memantine. J Neurosci. 2009;29(9):2774-2779. PubMed: 19261873.
  20. Khlestova E, Johnson JW, Krystal JH, Lisman J. The Role of GluN2C-Containing NMDA Receptors in Ketamine’s Psychotogenic Action and in Schizophrenia Models. J Neurosci. 2016;36(44):11151-11157. PubMed: 27807157.
  21. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17(8):2921-2927. PubMed: 9092613.
  22. Pozzi L, Pollak Dorocic I, Wang X, Carlen M, Meletis K. Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists. PLoS One. 2014;9(1):e83879. PubMed: 24454710.
  23. Nosyreva E, Szabla K, Autry AE, Ryazanov AG, Monteggia LM, Kavalali ET. Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci. 2013;33(16):6990-7002. PubMed: 23595756.
  24. Gideons ES, Kavalali ET, Monteggia LM. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci USA. 2014;111(23):8649-8654. PubMed: 24912158.
  25. Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11(10):682-696. PubMed: 20842175.
  26. Guo H, Lai L, Butchbach ME, Stockinger MP, Shan X, Bishop GA, et al. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet. 2003;12(19):2519.2532. PubMed: 12915461.
  27. Miller OH, Yang L, Wang CC, Hargroder EA, Zhang Y, Delpire E, et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. Elife. 2014;3:e03581. PubMed: 25340958.
  28. Kiselycznyk C, Jury NJ, Halladay LR, Nakazawa K, Mishina M, Sprengel R, et al. NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism. Behav Brain Res. 2015;287:89-95. PubMed: 25800971.
  29. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28(6):631-637. PubMed: 19011431.
  30. Hikosaka O. The habenula: from stress evasion to value-based decision-making. Nat Rev Neurosci. 2010;11(7):503-513. PubMed: 20559337.
  31. Boulos LJ, Darcq E, Kieffer BL. Translating the Habenula-From Rodents to Humans. Biol Psychiatry. 2017 Feb 15;81(4):296-305. 
  32. Derkach VA, Oh MC, Guire ES, Soderling TR. Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat Rev Neurosci. 2007;8(2):101-113. PubMed: 17237803.
  33. Zhou W, Wang N, Yang C, Li XM, Zhou ZQ, Yang JJ. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. European Psychiatry. 2014;29(7):419-423. PubMed: 24321772.
  34. Koike H, Chaki S. Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res. 2014;271:111-115. PubMed: 24909673.
  35. Wolak M, Siwek A, Szewczyk B, Poleszak E, Pilc A, Popik P, et al. Involvement of NMDA and AMPA receptors in the antidepressant-like activity of antidepressant drugs in the forced swim test. Pharmacol Rep. 2013;65(4):991-997. PubMed: 24145093.
  36. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012;64(2):238-258. PubMed: 22407616.
  37. Lepack AE, Fuchikami M, Dwyer JM, Banasr M, Duman RS. BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol. 2014;18(1):pyu033.
  38. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960-976.  https://doi.org/10.1016/j.cell.2017.02.004
  39. Switon K, et al. Molecular neurobiology of mTOR. Neuroscience. 2017;341:112-153.  https://doi.org/10.1016/j.neuroscience.2016.11.017
  40. Yang C, et al. Acute administration of ketamine in rats increases hippocampal BDNF andmTOR levels during forced swimming test. Ups J Med Sci. 2013;118:3-8.  https://doi.org/10.3109/03009734.2012.724118
  41. Li N, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959-964. 
  42. Dong C, et al. Rapid and sustained antidepressant action of the mGlu2/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine. Int J Neuropsychopharmacol. 2017;20:228-236. 
  43. Williams NR, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonisms. Am J Psychiatry. 2018;175:1205-1215.
  44. Zanos P, et al. Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharm Rev. 2018;70(3):621-660. 
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.